The MIND-BC Study: MIND Diet for Breast Cancer Cognition
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: MIND Diet, Usual Diet.
- Who it may be relevant to
- Registry conditions: Breast Cancer. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This fully, powered efficacy RCT, the MIND diet for Breast Cancer Cognition (MIND-BC), will evaluate the MIND diet in a rigorous, highly controlled academic cancer center. We will recruit breast cancer survivors reporting CRCI with a MIND diet score \< 8, based on a previously devised 14-item diet questionnaire designed to detect inadequate diet with respect to brain health (scores range from 0 to 14, with lower scores indicating a less adequate diet).14 Breast cancer survivors will have recently completed adjuvant treatment (i.e., 6 months to three years previously), to ensure that perceived cognitive impairment is likely chronic and due to cancer. To achieve maximal effect, the study consists of two 12-week phases 1) intervention phase, 2) maintenance phase.
Interventions
- Other MIND Diet
a combination of the Mediterranean and DASH diets emphasizing consumption of high-nutrient, plant-based foods such as green leafy vegetables, nuts, berries, fish, and olive oil while limiting intake of foods high in saturated fat, pre-processed snacks, sugar, red and processed meat. - Other Usual Diet
Check-in sessions for the usual diet arm will focus on general health (e.g., healthy hair, skin, eyesight). None of the topics will include dietary information for the usual diet arm.
Primary outcome measures
- Efficacy of the MIND diet: Self-reported cognition [Time frame: At 12 weeks and 3 months]
Secondary outcome measures (3)
- Efficacy of the MIND diet: Fatigue [Time frame: At 12 weeks and 3 months]
- Efficacy of the MIND diet: Quality of life (QOL) and mood [Time frame: At 12 weeks and 3 months]
- Efficacy of the MIND diet: Objective cognition [Time frame: At Baseline, 12 weeks, and 3 months]
Eligibility criteria
Inclusion criteria
- Previously diagnosed with stage I-III breast cancer.
- Able to speak and read English.
- Able to consume foods orally.
- >18 years of age.
- Able to provide informed consent.
- Have no documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g., schizophrenia).
- Report 'somewhat' to 'very much' cognitive impairment in the past week (i.e., a score ≥ 2 on a 0-4 scale) that they attribute to cancer or its treatment.
- Report a MIND diet score < 10 (range 0 to 14, higher score equates to higher diet quality).
- Willing to consume the MIND diet.
- Completed adjuvant treatment 6 months to three years previously.
Exclusion criteria
- Not meeting all of the inclusion criteria.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Supportive care
Study locations
United States · 1 center
- Moffitt Cancer Center — Tampa
Publications
- Crowder SL, Hu B, Hoogland AI, Li X, Rodriguez Y, Bryant C, Varghese DM, Simon DF, Reese SA, Carson TL, Han HS, Small BJ, Jim HSL. Rationale and study protocol for a randomized controlled MIND diet feeding trial for breast cancer-related cognitive impairment. Contemp Clin Trials. 2026 Jul;166:108355. doi: 10.1016/j.cct.2026.108355. Epub 2026 May 22. PMID 42173439
Identifiers
NCT: NCT07018986 · MCC-23571 · R01CA299480